Valued at USD 5.80 billion in 2024, the Cell Therapy Technologies Market is projected to reach USD 7.09 billion in 2025 and USD 44.43 billion by 2034, growing at a CAGR of 22.6% during the forecast period 2025–2034. Polaris Market Research attributes this trajectory to funding, precision tools such as CRISPR-Cas9, and rising demand for personalized medicine.

Government Funding and CRISPR-Cas9 Precision

Polaris identifies increased government funding and support for cell therapy R&D as a core driver, citing NIH grant programs and European Union collaborative initiatives. Advances in gene editing, particularly CRISPR-Cas9, improve precision and efficiency, strengthening the technology base on which cell therapy developers depend. For B2B suppliers of tools and consumables, CRISPR-Cas9 progress is a stated driver of the market. The report segments the market by therapy type, technology and application.

Regenerative Medicine and Growing Approvals

Growing approvals of cell-based therapies and growing investment in regenerative medicine are also stated drivers. Polaris further cites a 2021 World Health Organization report stating that by 2030 one in six people globally will be aged 60 or older, as context for the aging population and rising chronic disease prevalence it lists among market drivers. The rising prevalence of chronic diseases is expected to create opportunities for market participants. Together, approvals and regenerative medicine investment point to a widening commercial base.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/cell-therapy-technologies-market

Personalized Medicine and Therapy Design

Demand for personalized medicine is a stated driver of the Cell Therapy Technologies Market. Autologous therapies lead by therapy type because their personalized nature reduces the risk of immune rejection. Technological advances that improve efficiency and scalability complement this demand, and personalized medicine remains a central theme for developers and suppliers alike.

iPSC-Derived Approaches and Allogeneic Strategy

Among the trends Polaris identifies is a growing focus on allogeneic therapies, including iPSC-derived approaches. In September 2021, Adaptimmune partnered with Genentech on iPSC-derived approaches to allogeneic T-cell therapies. Allogeneic approaches are expected to see significant growth over the forecast period. Polaris also notes continuous innovation and strategic collaborations, partnerships and acquisitions among competitors.

Automated Cell Processing and Regional Manufacturing

Manufacturing technology is part of the competitive picture. In October 2024, Sino-Biocan (Shanghai) Biotech launched the WUKONG Automated Cell Processing System, an example of automated cell processing entering the market. Polaris also points to expansion in Asia Pacific, including local manufacturing in China, with the region expected to be the fastest-growing, driven by awareness of alternative therapies, investment and government policy. North America was the largest market in 2024, supported by advanced healthcare infrastructure, R&D investment and a supportive regulatory environment. For suppliers, automated cell processing aligns with the report's emphasis on efficiency and scalability.

Competitive Landscape: Key Players

Major players in the Cell Therapy Technologies Market include Agilent Technologies Inc., Avantor, Inc., Becton, Dickinson and Company, Bio-Techne Corporation, Corning Incorporated, Danaher Corporation, Fresenius SE & Co. KGaA, Lonza Group AG, Merck KGaA, Sartorius AG, Terumo Corporation and Thermo Fisher Scientific Inc.

Challenges and Strategic Outlook

Complex regulatory approval processes are the restraint Polaris identifies, and its Porter's Five Forces assessment rates rivalry among existing firms as high, the threat of new entrants as low, and supplier power, buyer power and the threat of substitutes as moderate. By application, oncology held the largest share in 2024, while musculoskeletal applications recorded the highest growth rate. By technology, viral vectors held the largest share and genome editing recorded the highest growth rate. The report uses 2024 as the base year, with historical data from 2020 to 2023.

Suppliers that connect CRISPR-Cas9, regenerative medicine, personalized medicine, iPSC-derived approaches and automated cell processing capabilities are aligned with the drivers and trends shaping the Cell Therapy Technologies Market.

More Trending Latest Reports By Polaris Market Research:

Cloud Based Contact Center Market

Robotic Palletizer Market

Robotic Platform Market

Lignans Market

Cell Isolation/Cell Separation Market

Anti-Counterfeit Packaging Market

Border Security Market

Oral Solid Dosage Contract Manufacturing Market

Maritime Patrol Aircraft Market

Digital Pharmacy Market